DEBASISH TRIPATHY to Humans
This is a "connection" page, showing publications DEBASISH TRIPATHY has written about Humans.
Connection Strength
0.550
-
Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment. Breast Cancer Res. 2023 06 06; 25(1):62.
Score: 0.017
-
Oral Oncolytics: Using Remote Technology to Improve Access, Operational Efficiency, and Satisfaction. Clin J Oncol Nurs. 2022 06 01; 26(3):308-312.
Score: 0.016
-
POLARIS: a prospective, multicenter, noninterventional study assessing palbociclib in hormone?receptor-positive advanced breast cancer. Future Oncol. 2020 Nov; 16(31):2475-2485.
Score: 0.014
-
Overall survival in older patients with cancer. BMJ Support Palliat Care. 2020 Mar; 10(1):25-35.
Score: 0.012
-
Mechanism of Action and Clinical Impact of Ribociclib-Response. Clin Cancer Res. 2017 09 15; 23(18):5658.
Score: 0.012
-
Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors. Clin Cancer Res. 2017 07 01; 23(13):3251-3262.
Score: 0.011
-
Modified Bi-Rads Scoring of Breast Imaging Findings Improves Clinical Judgment. Breast J. 2015 Nov-Dec; 21(6):642-50.
Score: 0.010
-
The BMC Medicine breast cancer collection: an illustration of contemporary research and clinical care. BMC Med. 2015 Sep 23; 13:223.
Score: 0.010
-
Integrative oncology - strong science is needed for better patient care. Nat Rev Cancer. 2015 Mar; 15(3):165.
Score: 0.010
-
Molecular markers for breast cancer diagnosis, prognosis and targeted therapy. J Surg Oncol. 2015 Jan; 111(1):81-90.
Score: 0.009
-
Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2014 Jun; 145(3):725-34.
Score: 0.009
-
Updates on the treatment of human epidermal growth factor receptor type 2-positive breast cancer. Curr Opin Obstet Gynecol. 2014 Feb; 26(1):27-33.
Score: 0.009
-
Awareness, concern, and communication between physicians and patients on bone health in cancer. Support Care Cancer. 2014 Jun; 22(6):1601-10.
Score: 0.009
-
Co-targeting estrogen receptor and HER2 pathways in breast cancer. Breast. 2014 Feb; 23(1):2-9.
Score: 0.009
-
First-line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER. Oncologist. 2013; 18(5):501-10.
Score: 0.009
-
New treatment paradigms for optimizing survival in advanced and metastatic breast cancer. Clin Adv Hematol Oncol. 2012 Aug; 10(8 Suppl 13):1-14; quiz 15-6.
Score: 0.008
-
Breast cancer quality care: what is at stake? Breast J. 2012 May-Jun; 18(3):201-2.
Score: 0.008
-
Using neoadjuvant therapy for breast cancer in clinical practice: when and how? Breast Cancer Res Treat. 2012 Apr; 132(3):775-7.
Score: 0.008
-
PARP inhibitors: the story is still unfolding. Oncology (Williston Park). 2011 Oct; 25(11):1028, 1030.
Score: 0.008
-
FDA and Avastin: crossroads in an era of targeted therapies. Oncology (Williston Park). 2010 Oct; 24(11):989-90.
Score: 0.007
-
Are we hitting the right combination for hormonally sensitive breast cancer? J Clin Oncol. 2009 Jun 01; 27(16):2580-2.
Score: 0.007
-
Novel taxane formulations in the treatment of breast cancer: a thought leader discussion and consensus roundtable. Clin Breast Cancer. 2008 Feb; 8(1):33-7.
Score: 0.006
-
Chinese medicinal herbs to treat the side-effects of chemotherapy in breast cancer patients. Cochrane Database Syst Rev. 2007 Apr 18; (2):CD004921.
Score: 0.006
-
Managing metastatic bone pain: the role of bisphosphonates. J Pain Symptom Manage. 2007 Apr; 33(4):462-72.
Score: 0.006
-
Capecitabine in combination with novel targeted agents in the management of metastatic breast cancer: underlying rationale and results of clinical trials. Oncologist. 2007 Apr; 12(4):375-89.
Score: 0.006
-
Integrative Oncology Practice Guidelines. J Soc Integr Oncol. 2007; 5(2):65-84.
Score: 0.006
-
Phase I trial and antitumor effects of BZL101 for patients with advanced breast cancer. Breast Cancer Res Treat. 2007 Sep; 105(1):17-28.
Score: 0.005
-
Patient and physician attitudes toward breast cancer clinical trials: developing interventions based on understanding barriers. Clin Breast Cancer. 2005 Apr; 6(1):45-54.
Score: 0.005
-
Targeted therapies in breast cancer. Breast J. 2005 Mar-Apr; 11 Suppl 1:S30-5.
Score: 0.005
-
Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial. Ann Oncol. 2005 Mar; 16(3):513; author reply 513.
Score: 0.005
-
Aromatase inhibitors: rationale and use in breast cancer. Annu Rev Med. 2005; 56:103-16.
Score: 0.005
-
Review of ibandronate in the treatment of metastatic bone disease: experience from phase III trials. Clin Ther. 2004 Dec; 26(12):1947-59.
Score: 0.005
-
Ibandronate reduces skeletal morbidity in patients with breast cancer. Semin Oncol. 2004 Oct; 31(5 Suppl 10):64-6.
Score: 0.005
-
Effect of cardiac dysfunction on treatment outcomes in women receiving trastuzumab for HER2-overexpressing metastatic breast cancer. Clin Breast Cancer. 2004 Oct; 5(4):293-8.
Score: 0.005
-
Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: Trial results and insights into "ARness". Cell Rep Med. 2024 Jun 18; 5(6):101595.
Score: 0.005
-
Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy. Clin Cancer Res. 2024 Jun 03; 30(11):2424-2432.
Score: 0.005
-
The challenges of randomized trials in integrative cancer care. Integr Cancer Ther. 2004 Jun; 3(2):112-27.
Score: 0.005
-
Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial. Ann Oncol. 2004 May; 15(5):743-50.
Score: 0.005
-
Premastectomy Radiotherapy and Immediate Breast Reconstruction: A Randomized Clinical Trial. JAMA Netw Open. 2024 Apr 01; 7(4):e245217.
Score: 0.005
-
Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol. 2004 Mar 15; 22(6):1063-70.
Score: 0.005
-
Efficacy of Single-Agent Chemotherapy in Endocrine Therapy-Refractory Metastatic Invasive Lobular Carcinoma. Oncologist. 2024 Mar 04; 29(3):213-218.
Score: 0.005
-
Systemic therapy for advanced breast cancer. Breast J. 2004 Jan-Feb; 10 Suppl 1:S26-7.
Score: 0.005
-
Oncogenes and tumor suppressor genes in breast cancer: potential diagnostic and therapeutic applications. Oncologist. 2004; 9(4):361-77.
Score: 0.005
-
Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast Cancer. JAMA Netw Open. 2023 12 01; 6(12):e2349646.
Score: 0.004
-
Absence of lobular carcinoma in situ is a poor prognostic marker in invasive lobular carcinoma. Eur J Cancer. 2023 09; 191:113250.
Score: 0.004
-
Biologically targeted therapy: as good as advertized? Clin Breast Cancer. 2003 Jun; 4(2):89.
Score: 0.004
-
Clinical testing of supplementation therapy in early stage breast cancer: pitfalls and opportunities. Integr Cancer Ther. 2003 Jun; 2(2):160-2.
Score: 0.004
-
Survival Outcomes in Patients With Hormone Receptor-Positive Metastatic Breast Cancer With Low or No ERBB2 Expression Treated With Targeted Therapies Plus Endocrine Therapy. JAMA Netw Open. 2023 05 01; 6(5):e2313017.
Score: 0.004
-
Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple-negative breast cancer. Cancer. 2023 07 15; 129(14):2201-2213.
Score: 0.004
-
Multidisciplinary care for breast cancer: barriers and solutions. Breast J. 2003 Jan-Feb; 9(1):60-3.
Score: 0.004
-
Traditional Chinese medicine in the treatment of breast cancer. Semin Oncol. 2002 Dec; 29(6):563-74.
Score: 0.004
-
Antiproliferative activity of Chinese medicinal herbs on breast cancer cells in vitro. Anticancer Res. 2002 Nov-Dec; 22(6C):3843-52.
Score: 0.004
-
Overview: gemcitabine as single-agent therapy for advanced breast cancer. Clin Breast Cancer. 2002 May; 3 Suppl 1:8-11.
Score: 0.004
-
Gemcitabine in breast cancer: future directions. Clin Breast Cancer. 2002 May; 3 Suppl 1:45-8.
Score: 0.004
-
Invasive lobular carcinoma: an understudied emergent subtype of breast cancer. Breast Cancer Res Treat. 2022 Jun; 193(2):253-264.
Score: 0.004
-
A Randomized Trial of Fulvestrant, Everolimus, and Anastrozole for the Front-line Treatment of Patients with Advanced Hormone Receptor-positive Breast Cancer, SWOG S1222. Clin Cancer Res. 2022 02 15; 28(4):611-617.
Score: 0.004
-
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. N Engl J Med. 2021 12 16; 385(25):2336-2347.
Score: 0.004
-
Bisphosphonates in oncology: breast cancer and beyond. Semin Oncol. 2001 Aug; 28(4 Suppl 11):86-91.
Score: 0.004
-
Anti-GD2 antibody dinutuximab inhibits triple-negative breast tumor growth by targeting GD2+ breast cancer stem-like cells. J Immunother Cancer. 2021 03; 9(3).
Score: 0.004
-
Complementary and alternative medicine in early-stage breast cancer. Semin Oncol. 2001 Feb; 28(1):121-34.
Score: 0.004
-
Validation of plasma metabolites associated with breast cancer risk among Mexican Americans. Cancer Epidemiol. 2020 12; 69:101826.
Score: 0.004
-
Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial. JAMA Oncol. 2020 09 01; 6(9):1355-1362.
Score: 0.004
-
Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer. JAMA Oncol. 2020 04 01; 6(4):505-511.
Score: 0.003
-
Factors associated with MRI detection of occult lesions in newly diagnosed breast cancers. J Surg Oncol. 2020 Mar; 121(4):589-598.
Score: 0.003
-
What symptoms are important to patients? Developing a symptom burden measure for women with breast cancer. Support Care Cancer. 2019 Dec; 27(12):4639-4647.
Score: 0.003
-
Breast cancer risk in relation to plasma metabolites among Hispanic and African American women. Breast Cancer Res Treat. 2019 Aug; 176(3):687-696.
Score: 0.003
-
MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial. J Clin Oncol. 2020 04 01; 38(10):1059-1069.
Score: 0.003
-
Cooperative Effect of Oncogenic MET and PIK3CA in an HGF-Dominant Environment in Breast Cancer. Mol Cancer Ther. 2019 02; 18(2):399-412.
Score: 0.003
-
Evaluation of cMET aberration by immunohistochemistry and fluorescence in situ hybridization (FISH) in triple negative breast cancers. Ann Diagn Pathol. 2018 Aug; 35:69-76.
Score: 0.003
-
Neurocognitive deficits in older patients with cancer. J Geriatr Oncol. 2018 09; 9(5):482-487.
Score: 0.003
-
Fractures frequently occur in older cancer patients: the MD Anderson Cancer Center experience. Support Care Cancer. 2018 May; 26(5):1561-1568.
Score: 0.003
-
Androgen Receptor Function and Androgen Receptor-Targeted Therapies in Breast Cancer: A Review. JAMA Oncol. 2017 Sep 01; 3(9):1266-1273.
Score: 0.003
-
Adaptive Randomization of Neratinib in Early Breast Cancer. N Engl J Med. 2016 Jul 07; 375(1):11-22.
Score: 0.003
-
Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. N Engl J Med. 2016 Jul 07; 375(1):23-34.
Score: 0.003
-
Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance). J Clin Oncol. 2016 08 01; 34(22):2602-9.
Score: 0.003
-
Incidence of Atypical Femur Fractures in Cancer Patients: The MD Anderson Cancer Center Experience. J Bone Miner Res. 2016 08; 31(8):1569-76.
Score: 0.003
-
Recurrence and survival among breast cancer patients achieving a pathological complete response to neoadjuvant chemotherapy. Breast Cancer Res Treat. 2015 Sep; 153(2):417-23.
Score: 0.003
-
Validation and Development of a Modified Breast Graded Prognostic Assessment As a Tool for Survival in Patients With Breast Cancer and Brain Metastases. J Clin Oncol. 2015 Jul 10; 33(20):2239-45.
Score: 0.002
-
The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer. Clin Cancer Res. 2015 Jul 01; 21(13):2911-5.
Score: 0.002
-
Functional consequence of the MET-T1010I polymorphism in breast cancer. Oncotarget. 2015 Feb 20; 6(5):2604-14.
Score: 0.002
-
Expression profiling of circulating tumor cells in metastatic breast cancer. Breast Cancer Res Treat. 2015 Jan; 149(1):121-31.
Score: 0.002
-
The efficacy and safety of oral ibandronate in the treatment of metastatic bone disease in patients with breast cancer. Ann Oncol. 2004 Oct; 15(10):1574; author reply 1574-5.
Score: 0.002
-
How long should adjuvant tamoxifen be continued? Oncology (Williston Park). 1994 Oct; 8(10):25-33; discussion 33, 37-8.
Score: 0.002
-
Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER. Br J Cancer. 2014 May 27; 110(11):2756-64.
Score: 0.002
-
Randomized controlled trial to evaluate the effects of combined progressive exercise on metabolic syndrome in breast cancer survivors: rationale, design, and methods. BMC Cancer. 2014 Apr 03; 14:238.
Score: 0.002
-
Radiologist's role in breast cancer staging: providing key information for clinicians. Radiographics. 2014 Mar-Apr; 34(2):330-42.
Score: 0.002
-
Growth factors and their receptors. Hematol Oncol Clin North Am. 1994 Feb; 8(1):29-50.
Score: 0.002
-
Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2013 Oct; 141(3):461-70.
Score: 0.002
-
Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol. 2003 Sep; 14(9):1399-405.
Score: 0.002
-
Prolactin-induced protein (PIP) regulates proliferation of luminal A type breast cancer cells in an estrogen-independent manner. PLoS One. 2014; 8(6):e62361.
Score: 0.002
-
Developing safety criteria for introducing new agents into neoadjuvant trials. Clin Cancer Res. 2013 Jun 01; 19(11):2817-23.
Score: 0.002
-
Systemic adjuvant therapy for breast cancer. Curr Opin Oncol. 1992 Dec; 4(6):1041-9.
Score: 0.002
-
Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug development. J Clin Oncol. 2012 Dec 20; 30(36):4584-6; author reply 4588-9.
Score: 0.002
-
Blood oxygenation level-dependent (BOLD) contrast magnetic resonance imaging (MRI) for prediction of breast cancer chemotherapy response: a pilot study. J Magn Reson Imaging. 2013 May; 37(5):1083-92.
Score: 0.002
-
Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study. Breast Cancer Res Treat. 2012 Oct; 135(3):875-83.
Score: 0.002
-
Adoption, acceptability, and accuracy of an online clinical trial matching website for breast cancer. J Med Internet Res. 2012 Jul 11; 14(4):e97.
Score: 0.002
-
Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. J Clin Oncol. 2012 Sep 10; 30(26):3242-9.
Score: 0.002
-
Activated oncogenes and putative tumor suppressor genes involved in human breast cancers. Cancer Treat Res. 1992; 63:15-60.
Score: 0.002
-
Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat. 2012 Apr; 132(3):1049-62.
Score: 0.002
-
Regulation of breast cancer metastasis by Runx2 and estrogen signaling: the role of SNAI2. Breast Cancer Res. 2011; 13(6):R127.
Score: 0.002
-
Opposing effects of Runx2 and estradiol on breast cancer cell proliferation: in vitro identification of reciprocally regulated gene signature related to clinical letrozole responsiveness. Clin Cancer Res. 2012 Feb 01; 18(3):901-11.
Score: 0.002
-
Locally advanced breast cancers are more likely to present as Interval Cancers: results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial). Breast Cancer Res Treat. 2012 Apr; 132(3):871-9.
Score: 0.002
-
Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res. 2011 Jul 15; 17(14):4834-43.
Score: 0.002
-
Trajectories of pain and analgesics in oncology outpatients with metastatic bone pain during participation in a psychoeducational intervention study to improve pain management. J Pain. 2011 Jun; 12(6):652-66.
Score: 0.002
-
Trajectories of pain and analgesics in oncology outpatients with metastatic bone pain. J Pain. 2011 Apr; 12(4):495-507.
Score: 0.002
-
Proceedings of the First Global Workshop on Breast Cancer: pathways to the evaluation and clinical development of novel agents for breast cancer. Clin Breast Cancer. 2010 Dec 01; 10(6):421-39.
Score: 0.002
-
A phase 1B dose escalation trial of Scutellaria barbata (BZL101) for patients with metastatic breast cancer. Breast Cancer Res Treat. 2010 Feb; 120(1):111-8.
Score: 0.002
-
Special report: Consensus conference III. Image-detected breast cancer: state-of-the-art diagnosis and treatment. J Am Coll Surg. 2009 Oct; 209(4):504-20.
Score: 0.002
-
Survival impact of integrative cancer care in advanced metastatic breast cancer. Breast J. 2009 Jul-Aug; 15(4):357-66.
Score: 0.002
-
Complete heart block with myocardial membrane-bound glycogen and normal peripheral alpha-glucosidase activity. Ann Intern Med. 1988 Dec 15; 109(12):985-7.
Score: 0.002
-
The use of a responder analysis to identify differences in patient outcomes following a self-care intervention to improve cancer pain management. Pain. 2007 May; 129(1-2):55-63.
Score: 0.001
-
Differences in the prevalence and severity of side effects based on type of analgesic prescription in patients with chronic cancer pain. J Pain Symptom Manage. 2007 Jan; 33(1):67-77.
Score: 0.001
-
uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues. Proc Natl Acad Sci U S A. 2006 Nov 14; 103(46):17361-5.
Score: 0.001
-
Efficacy of sequential treatment of HCT116 colon cancer monolayers and xenografts with docetaxel, flavopiridol, and 5-fluorouracil. Acta Pharmacol Sin. 2006 Oct; 27(10):1375-81.
Score: 0.001
-
Intravenous ibandronate does not affect time to renal function deterioration in patients with skeletal metastases from breast cancer: phase III trial results. Eur J Cancer Care (Engl). 2006 Jul; 15(3):299-302.
Score: 0.001
-
Safety of oral ibandronate in the treatment of bone metastases from breast cancer : long-term follow-up experience. Clin Drug Investig. 2006; 26(1):43-8.
Score: 0.001
-
Image-detected breast cancer: state of the art diagnosis and treatment. J Am Coll Surg. 2005 Oct; 201(4):586-97.
Score: 0.001
-
Qualitative research contribution to a randomized clinical trial. Res Nurs Health. 2005 Jun; 28(3):268-80.
Score: 0.001
-
MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival. AJR Am J Roentgenol. 2005 Jun; 184(6):1774-81.
Score: 0.001
-
Pegylated liposomal doxorubicin and cyclophosphamide as first-line therapy for patients with metastatic or recurrent breast cancer. Clin Breast Cancer. 2005 Jun; 6(2):150-7.
Score: 0.001
-
Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res. 2004 Dec 15; 10(24):8152-62.
Score: 0.001
-
The PRO-SELF pain control program improves patients' knowledge of cancer pain management. Oncol Nurs Forum. 2004 Nov 16; 31(6):1137-43.
Score: 0.001
-
Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain. 2004 Oct; 111(3):306-312.
Score: 0.001
-
Efficacy of radiotherapy for ovarian ablation: results of a breast intergroup study. Cancer. 2004 Sep 01; 101(5):969-72.
Score: 0.001
-
No evidence for sex differences in the severity and treatment of cancer pain. J Pain Symptom Manage. 2004 Sep; 28(3):225-32.
Score: 0.001
-
HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci U S A. 2004 Jun 22; 101(25):9393-8.
Score: 0.001
-
Randomized clinical trial of the effectiveness of a self-care intervention to improve cancer pain management. J Clin Oncol. 2004 May 01; 22(9):1713-20.
Score: 0.001
-
Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer. 2004 Mar 22; 90(6):1133-7.
Score: 0.001
-
Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. J Clin Oncol. 2003 Mar 15; 21(6):999-1006.
Score: 0.001
-
The PRO-SELF(c): Pain Control Program--an effective approach for cancer pain management. Oncol Nurs Forum. 2003 Jan-Feb; 30(1):65-73.
Score: 0.001
-
The usefulness of a daily pain management diary for outpatients with cancer-related pain. Oncol Nurs Forum. 2002 Oct; 29(9):1304-13.
Score: 0.001
-
Putting cancer pain management regimens into practice at home. J Pain Symptom Manage. 2002 May; 23(5):369-82.
Score: 0.001
-
Pain management autobiographies and reluctance to use opioids for cancer pain management. Cancer Nurs. 2002 Apr; 25(2):125-33.
Score: 0.001
-
Point-counterpoint: soy intake for breast cancer patients. Integr Cancer Ther. 2002 Mar; 1(1):90-100.
Score: 0.001
-
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002 Feb 01; 20(3):719-26.
Score: 0.001
-
Lack of adherence with the analgesic regimen: a significant barrier to effective cancer pain management. J Clin Oncol. 2001 Dec 01; 19(23):4275-9.
Score: 0.001
-
MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer. Ann Surg Oncol. 2001 Jul; 8(6):549-59.
Score: 0.001
-
First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: a preliminary report. Eur J Cancer. 2001 Jan; 37 Suppl 1:S25-9.
Score: 0.001
-
First-line Herceptin monotherapy in metastatic breast cancer. Oncology. 2001; 61 Suppl 2:37-42.
Score: 0.001
-
Building bridges between physicians and patients: results of a pilot study examining new tools for collaborative decision making in breast cancer. J Clin Oncol. 2000 Mar; 18(6):1230-8.
Score: 0.001
-
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999 Sep; 17(9):2639-48.
Score: 0.001
-
Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol. 1999 Aug; 26(4 Suppl 12):78-83.
Score: 0.001
-
Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol. 1998 Aug; 16(8):2659-71.
Score: 0.001
-
Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol. 1996 Mar; 14(3):737-44.
Score: 0.001
-
Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat. 1992; 24(2):85-95.
Score: 0.000